– USA, GA – Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced the addition of Wendy Perrow to its Board of Directors, bringing decades of experience in the life sciences industry related to fundraising, global product launches, and corporate strategy.
Concurrently, the company announced that board member William Witte has resigned.
“We are thrilled to have Wendy join our board and be able to tap into her experience at a key time, as we progress with our de novo clinical trial for FemaSeed, our localized directional insemination product candidate for infertility, and, just as we gear up for the pivotal trial later this year for our permanent birth control product candidate, FemBloc,” said founder and CEO, Kathy Lee-Sepsick.
He added: “Wendy brings to the board a strong and proven track record of topline vision and corporate strategy, as well as high-level tactical expertise in marketing, business and product development, and fundraising. All of which will prove to be incredibly beneficial as we steer Femasys forward with our commercial assets in tandem with the clinical progression of our lead product candidates.”
About Wendy Perrow
Ms. Perrow brings a proven record of company-building and fundraising, in addition to corporate strategy, business and product development, regulatory, manufacturing, and marketing in the life sciences. Most recently, Ms. Perrow was CEO of AsclepiX Therapeutics, Inc., an early-stage biotechnology company developing novel peptide therapeutics for indications in retinal diseases and oncology. She also served as an AsclepiX board member. Before this, Ms. Perrow was CEO of Alba Therapeutics, Inc., a clinical-stage biotechnology company developing novel therapeutics for autoimmune and gastrointestinal diseases. During this time. Ms. Perrow was instrumental in raising $31 million via a partnership with Cephalon, the proceeds of which funded a Phase 2b clinical trial and closed a deal with Innovate Biopharmaceuticals, Inc. (now 9 Meters Biopharma). Before this, at Sigma-Tau Pharmaceuticals, Inc., as VP of business development, marketing and sales, Ms. Perrow drove the estimated market value of the company by 515% in three years and championed the first global Hodgkin Lymphoma trial led by thought leader, Volker Diehl, M.D.
Throughout her career, Ms. Perrow has led the creation of companies focused on ophthalmology and oncology, and she has launched world-renowned products in cholesterol, vaccines, and hypertension yielding multi-billion dollars in sales, as well as closed a multi-million dollar out-licensing deal for a first-of-its-kind phase 2 asset. Ms. Perrow additionally has diverse global business experience working with the U.S., European, Pan-Asian, and Latin American markets.
Ms. Perrow said, “I am excited to be joining the Femasys Board at a time when we are in a position to leverage the company’s lead product candidates, FemBloc and FemaSeed, pre-market. My background lies in maximizing value for breakthrough assets with novel mechanisms of action, so I am eager to be able to offer my expertise and contribute to maximizing the value of these product candidates as they progress towards potential commercialization, as well as maximize the company’s overall corporate strategy as it matures following its entry in the public markets.”
Ms. Perrow received her MBA in Finance and Marketing from Duke University, The Fuqua School of Business and has an undergraduate degree, magna cum laude, in Education from Eastern Illinois University. Ms. Perrow sits on several boards and is a member of Women in Bio.
About Femasys
Femasys Inc. is a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc permanent birth control and FemaSeed localized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound, FemVue, is currently marketed in the United States. Femasys is also advancing FemCerv, a technology platform for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.
For more information: https://www.femasys.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.